Integrated Wealth Concepts’s Keros Therapeutics KROS Stock Holding History

Integrated Wealth Concepts’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17K	Buy	+1,587	New	+$17.7K	﹤0.01%	4208

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Integrated Wealth Concepts's KROS Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Keros Therapeutics (KROS) in Q2 2026: 1,587 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #4208 among its holdings.

132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Integrated Wealth Concepts held 1,587 shares of Keros Therapeutics worth $17K as of Q2 2026.
Keros Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
Keros Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #4208 holding.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.